Robert A. Michael Appointed as CEO of AbbVie
AbbVie announced today that Robert A. Michael has taken on the role of Chief Executive Officer (CEO) and joined the company’s Board of Directors, effective immediately. As previously announced, Mr.…
Read MoreRobert A. Michael Appointed as CEO of AbbVie
Merck Secures Global Rights to Opevesostat for Prostate Cancer
MSD (known as Merck & Co., Inc. in the US and Canada) and Orion Corporation announced the mutual exercise of an option to convert their co-development and co-commercialization agreement for…
Merck Announces Second-Quarter 2024 Sales and Earnings Conference Call on July 30
MSD, known as Merck outside the United States and Canada, will host its second-quarter 2024 sales and earnings conference call for institutional investors and analysts at 9:00 a.m. ET on…
UCB Showcases Latest Insights on Newly Launched gMG Portfolio at EAN Congress
UCB, a global biopharmaceutical company, has unveiled new research findings supporting its recently launched treatments in the generalized myasthenia gravis (gMG) portfolio. These findings will be presented at the 10th…
Pfizer, BioNTech Get CHMP Nod for Omicron JN.1-adapted COVID-19 Vaccine in EU
Sure, here’s a rewritten version of the article: Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
LEQEMBI® (Lecanemab) Launches in China for Alzheimer’s Disease Treatment
Biogen, headquartered in Cambridge, Massachusetts, and led by CEO Christopher A. Viehbacher, announced today the launch of “LEQEMBI®” (known as “乐意保®” in China), a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal…
Frexalimab Phase 2 Results: Reduction of Key Biomarker of Nerve Cell Damage in Relapsing MS
Sanofi’s CD40L monoclonal antibody, frexalimab, has demonstrated promising results in reducing a key biomarker associated with nerve cell damage in patients with relapsing multiple sclerosis (MS), suggesting potential benefits in…
Pfizer and BioNTech Granted Favorable CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of their Omicron JN.1-adapted monovalent…
EU Approval Recommended for Roche’s PiaSky in PNH Treatment
Roche’s PiaSky Receives Positive CHMP Opinion for PNH Treatment in EU Today, Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended PiaSky®…
Roche’s Vabysmo Receives CHMP Recommendation for Third Indication: Retinal Vein Occlusion (RVO)
Roche announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for extending the marketing authorization of Vabysmo® (faricimab) to…
CDC Recommends Merck’s 21-Valent Pneumococcal Vaccine for Adults
Merck known as MSD outside the United States and Canada, announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has unanimously recommended…
Merck Gains Positive EU CHMP Opinion for WINREVAIR™ (Sotatercept) in Treating Pulmonary Arterial Hypertension (PAH)
Merck Announces Positive EU CHMP Recommendation for WINREVAIR™ (Sotatercept) in Treating Pulmonary Arterial Hypertension (PAH) Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that…